Oncology Institute (TOI) to Release Earnings on Thursday

Oncology Institute (NASDAQ:TOI) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Oncology Institute to post earnings of ($0.07) per share and revenue of $155.28 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 5:00 PM ET.

Oncology Institute (NASDAQ:TOI) last released its earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The firm had revenue of $147.44 million for the quarter, compared to the consensus estimate of $142.10 million. On average, analysts expect Oncology Institute to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Oncology Institute Price Performance

Shares of Oncology Institute stock opened at $5.19 on Wednesday. The firm has a market cap of $512.58 million, a price-to-earnings ratio of -14.02 and a beta of 0.38. The stock’s 50-day moving average is $5.20 and its 200-day moving average is $3.93. Oncology Institute has a one year low of $2.32 and a one year high of $6.67.

Analysts Set New Price Targets

TOI has been the topic of a number of recent research reports. BTIG Research lifted their target price on Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research report on Friday, July 17th. Needham & Company LLC raised their price target on shares of Oncology Institute from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Finally, Lake Street Capital began coverage on shares of Oncology Institute in a report on Monday, July 6th. They issued a “buy” rating and a $10.00 price objective on the stock. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Oncology Institute currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Insider Buying and Selling

In other news, major shareholder Jorey Chernett bought 18,000 shares of the firm’s stock in a transaction dated Tuesday, July 21st. The shares were bought at an average price of $5.27 per share, with a total value of $94,860.00. Following the completion of the transaction, the insider owned 10,648,858 shares of the company’s stock, valued at $56,119,481.66. This trade represents a 0.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Yale Podnos sold 23,451 shares of Oncology Institute stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $5.38, for a total value of $126,166.38. Following the sale, the insider directly owned 259,527 shares of the company’s stock, valued at approximately $1,396,255.26. The trade was a 8.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have bought 131,500 shares of company stock valued at $609,265. Corporate insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Oncology Institute

Hedge funds and other institutional investors have recently modified their holdings of the company. Kanen Wealth Management LLC bought a new stake in shares of Oncology Institute in the third quarter valued at about $6,421,000. Marshall Wace LLP bought a new position in Oncology Institute during the second quarter worth about $3,028,000. Geode Capital Management LLC increased its position in Oncology Institute by 231.7% during the second quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company’s stock worth $2,623,000 after acquiring an additional 893,696 shares during the period. UBS Group AG raised its stake in Oncology Institute by 151.2% in the 3rd quarter. UBS Group AG now owns 1,055,862 shares of the company’s stock worth $3,685,000 after purchasing an additional 635,489 shares in the last quarter. Finally, Millennium Management LLC raised its stake in Oncology Institute by 134.8% in the 3rd quarter. Millennium Management LLC now owns 951,001 shares of the company’s stock worth $3,319,000 after purchasing an additional 545,992 shares in the last quarter. Institutional investors and hedge funds own 36.86% of the company’s stock.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.